Serena Marchiò is an Associate Professor in the Department of Oncology at the University of Turin, specializing in biochemistry (SSD: BIO/10). She is affiliated with the Candiolo Cancer Institute, FPO-IRCCS, located in Candiolo, Italy. Her academic work spans teaching and research in oncology, with a particular focus on cancer biology and therapeutic development. Dr. Marchiò teaches Biochemistry, cellular and molecular biology across multiple programs including the Artificial Intelligence for Biomedicine and Healthcare program, Dental Hygiene degree, Veterinary Medicine program, and the Medicine and Surgery program at the University of Turin. Her teaching portfolio includes courses on structural biochemistry, proteomics, and multi-omics for precision medicine. Her primary research focus is on the tumor microenvironment, utilizing a phage display-based platform that integrates high-throughput screenings, next-generation sequencing, and bioinformatics. For over 25 years, her work has centered on identifying molecular markers and reconstructing protein-protein interactions in various tumor types. This approach has enabled her team to discover new blood-accessible targets and develop targeted theranostic nanosystems for cancer treatment. Analysis of her recent publications reveals a strong emphasis on advanced drug delivery systems, particularly nanoparticles and phage-based technologies for cancer therapy. Her work spans multiple cancer types including cholangiocarcinoma, prostate cancer, osteosarcoma, and neuroblastoma, with a consistent focus on overcoming drug resistance and improving targeted delivery. The integration of nanotechnology with molecular targeting represents a key thread throughout her research portfolio. Dr. Marchiò serves on several academic bodies including the Department Council and the Teaching Commission of the Department of Oncology at the University of Turin. She leads an AIRC-funded project (FRidA) focused on cancer research, demonstrating sustained external funding for her work. Her laboratory combines expertise in molecular biology, nanotechnology, and cancer biology to develop innovative approaches for cancer diagnosis and treatment. The research group maintains strong collaborations with clinical and basic science researchers, facilitating the translation of laboratory discoveries toward clinical applications.